Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b ...
Zacks Investment Research on MSN
PFE stock slides following CFO exit, 2026 guidance reaffirmed
Shares of Pfizer PFE declined nearly 3% on Thursday after the company announced the departure of its chief financial officer ...
Pfizer is rated a Buy with 55%+ upside potential, driven by a robust pipeline and undervalued forward earnings. Read more on ...
Cecile Guegan will serve as interim CFO, Pfizer said. ・The company said it will provide additional details on the permanent ...
Pfizer announced that Chief Financial Officer Dave Denton will leave the company in August to pursue an external opportunity.
Pfizer (PFE) stock drops as CFO Dave Denton will resign Aug. 15; Cecile Guegan is named interim CFO as the company launches ...
Pfizer returns to market focus after a finance leadership transition, prompting fresh discussion around valuation, pipeline ...
Pfizer (PFE) stock drops 3% as CFO Dave Denton reveals August exit. Cecile Guegan appointed interim CFO while company ...
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...
Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per ...
Pfizer said on Thursday that finance chief Dave Denton will step down and leave the company on August 15 to take a role in the consumer goods industry.
Pfizer (PFE) shares dropped 3% following CFO Dave Denton's departure announcement. Cecile Guegan will serve as interim CFO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results